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Background: Epidermal growth factor (EGF) receptors contribute to the development of malignant glioma. Here
we considered the possible implication of the EGFR ligand epiregulin (EREG) in glioma development in relation to
the activity of the unfolded protein response (UPR) sensor IRE1α. We also examined EREG status in several
glioblastoma cell lines and in malignant glioma.
Methods: Expression and biological properties of EREG were analyzed in human glioma cells in vitro and in human
tumor xenografts with regard to the presence of ErbB proteins and to the blockade of IRE1α. Inactivation of IRE1α
was achieved by using either the dominant-negative strategy or siRNA-mediated knockdown.
Results: EREG was secreted in high amounts by U87 cells, which also expressed its cognate EGF receptor (ErbB1). A
stimulatory autocrine loop mediated by EREG was evidenced by the decrease in cell proliferation using specific
blocking antibodies directed against either ErbB1 (cetuximab) or EREG itself. In comparison, anti-ErbB2 antibodies
(trastuzumab) had no significant effect. Inhibition of IRE1α dramatically reduced EREG expression both in cell
culture and in human xenograft tumor models. The high-expression rate of EREG in U87 cells was therefore
linked to IRE1α, although being modestly affected by chemical inducers of the endoplasmic reticulum stress. In
addition, IRE1-mediated production of EREG did not depend on IRE1 RNase domain, as neither the selective
dominant-negative invalidation of the RNase activity (IRE1 kinase active) nor the siRNA-mediated knockdown of
XBP1 had significant effect on EREG expression. Finally, chemical inhibition of c-Jun N-terminal kinases (JNK)
using the SP600125 compound reduced the ability of cells to express EREG, demonstrating a link between the
growth factor production and JNK activation under the dependence of IRE1α.
Conclusion: EREG may contribute to glioma progression under the control of IRE1α, as exemplified here by the
autocrine proliferation loop mediated in U87 cells by the growth factor through ErbB1.Background
Malignant gliomas are highly aggressive tumors and their
treatment still remains a challenging issue. The moderate
efficacy of current clinical approaches underline the need
for new therapeutic strategies [1]. Some of these focus on
the inhibition of EGF receptors, collectively referred to as
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reproduction in any medium, provided the orreceptor family comprises four related members, ErbB1 to
ErbB4, which are bound and activated by a set of thirteen
distinct EGF-related peptide growth factors [2].
Amplification of ErbB1 and alteration of its activity
are important contributors to glioma development
[3,4]. For these reasons, phase II trials for high-grade
gliomas have been targeting ErbB1 by using either hu-
manized antibodies directed against the receptor extra-
cellular domain (cetuximab, trade name Erbitux®), or
pharmacological inhibitors of its protein kinase activity
(erlotinib, gefinitib) [1,3,4]. The participation of the. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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progression by deregulation of ErbB signaling networks
has also been considered [4-7].
The possible involvement of the EGF-like growth fac-
tors in glioma development was also questioned. An oc-
casional increase of EGF, TGF-α or HB-EGF expression
has been reported in malignant gliomas. Up-regulation
of these growth factors may sustain autocrine loops
[8-11] and contribute to tumor cell proliferation, inva-
sion, survival and resistance to therapy [2,4].
EREG is a growth regulating peptide and a member of
the EGF family mainly observed in placenta and periph-
eral blood macrophages in normal human tissues [12].
At the molecular level, EREG activates ErbB1 and ErbB4
homodimers as well as heterodimeric combinations of
these two proteins and other EGF receptors [13,14].
EREG binds to ErbB1 with a lower affinity than EGF
while exhibiting a higher mitogenic potential. This ap-
parent inconsistency was explained by the prolonged
stimulation of its receptors [13,15]. Because of its broad
binding spectrum to ErbB proteins and high biological
potency, EREG represents an influential activator of
ErbB-dependent signaling networks in cancer. EREG is
up-regulated in carcinoma cell lines [12] and is associ-
ated to the progression of breast, bladder and pancreatic
carcinomas [16-18]. EREG is also an independent pre-
dictor of liver and lung metastasis in colorectal and
bladder cancers, respectively [19,20].
To our knowledge, a single study considered EREG ex-
pression in glioma [21]. Previously, we showed that in-
hibition of the Unfolded Protein Response (UPR) sensor
IRE1α (also named ERN1) down-regulated the expres-
sion of several pro-angiogenic growth factors in a glioma
model [22]. Interestingly, the level of EREG transcripts
was also strongly reduced in these conditions (GEO
database, accession n° GSE22385), raising the hypothesis
that its expression may be related to the endoplasmic
reticulum (ER) physiology. Since EREG contributes to
the angiogenesis process as well as to tumor metastasis
in breast carcinoma models [23], we further considered
its possible relationship to IRE1α and to glioma develop-
ment and analyzed its status in several glioblastoma cell
lines and in malignant glioma.
Methods
Reagents
Culture media were from Invitrogen (Cergy-Pontoise,
France). Antibodies against ErbB1 were purchased from
BD Biosciences (San Diego, USA). Anti-ErbB2 and anti-
phospho-JNK (Thr183/Tyr185) were from Cell Signaling
(Saint-Quentin-en-Yvelines, France). Anti-phospho-Tyr1173-
ErbB1 was from Millipore (Molsheim, France). Anti-β-actin
and anti-JNK antibodies were from Santa Cruz Biotechnol-
ogy (Santa Cruz, USA). Recombinant EREG, monoclonaland polyclonal antibodies against EREG and control mouse
monoclonal (isotype IgG1) antibodies were from R&D Sys-
tems (Minneapolis, USA). Secondary goat-anti-mouse anti-
bodies coupled to biotin or to peroxidase were from DAKO
(Trappes, France). Humanized anti-ErbB1 (Erbitux®, cetuxi-
mab) and anti-ErbB2 (Herceptin®, trastuzumab) antibodies
were kindly provided by Merck Serono (Darmstadt,
Germany) and by Roche (Mannheim, Germany), re-
spectively. Primers are indicated in Additional file 1.
Cloning
The dominant-negative IRE1 RNase mutant (IRE1Δ899;
GenBank accession number JQ425696) was obtained by
truncation of the carboxy-terminal 78 amino acids of
IRE1α. The mutant was obtained by inserting a gatc motif
at position 2812 of the BglII restriction site 2799tctgtcaga-
gatc “gatc” tcctccgagccatgagaaataa2833. The frameshift in-
sertion generates a stop codon 19 bases later. The wild
type IRE1α amino acids sequence at positions 896–907
is –SVRDLLRAMRNK- and the C-terminal sequence
of the mutant is –SVRDRSPPSHEK-COO–. The final
sequence was controlled by DNA sequencing and was
cloned in a pcDNA3 plasmid before transfection in
U87wt cells and selection at 800 μg/ml G418.
Cell culture
U87-MG (U87wt) cells were from ATCC (HTB-14).
SF126 and SF188 cells were kindly provided by Dr. M.
Czabanka (Charité Universitätsmedizin, Berlin). Cells
were grown at 37°C, 10% CO2 in DMEM, 4.5 g/l glu-
cose supplemented with 10% FBS, L-glutamine and an-
tibiotics. Empty plasmid U87 (U87Ctrl) cells, U87 IRE1dn
(U87dn) cells [22] and U87 IRE1Δ899 (U87Δ899) cells
were grown in the presence of 500 μg/ml G418 and were
used at passages 8–13 after transfection. The immortal-
ized human astrocyte NHA/TS cell line and its tumori-
genic NHA/TSR counterpart were kindly provided by Drs
K. Sasai and S. Tanaka and were grown as reported [24].
Proliferation and migration assays
Proliferation assay was performed in 96-well plates with
DMEM containing 1% FCS and 30 ng/ml EREG. Serial
propagation of cells in the absence of serum was devel-
oped as previously reported [25]. Briefly, cells were
plated at 10 000 cells/cm2 in fibronectin-precoated 24-
well plates. The serum-free complete medium consisted
of a 1 to 1 mixture of DME/F12 medium, 1 mg/ml fatty-
acid free BSA, 50 μg/ml high-density lipoproteins, 5 μg/ml
transferrin, 5 μg/ml insulin with or without 10 ng/ml
EREG. The medium was renewed every 3 days and cells
were passaged after 9 days of culture. Cells were counted
by using a cell counter (Coultronics, Margency, France).
The transwell migration assays was performed as de-
scribed previously [22]. Results were analyzed after
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dition and by three independent investigators.
Immunoblot analysis
Subconfluent cells were lysed at 4°C with 100 mM Tris–
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4,
5 mM NaF, protease inhibitors (P8340; Sigma), SDS 1%.
The cytosolic fraction was obtained by centrifugation for
2 min at 7000 rpm. After migration on SDS-PAGE, pro-
teins were transferred to a nitrocellulose membrane and
probed using antibodies against phospho- and total ErbB
proteins, phospho- and total JNK proteins, β-actin or
α-tubulin. Primary antibodies were revealed with a sec-
ondary HRP-antibody and detected by ELS Western
bloting detection reagents (Amersham), or with a sec-
ondary antibody coupled to IRDye 800CW using the
Odyssey infrared imaging system (Li-Cor Biosciences,
Nebraska, US).
ELISA against EREG
Conditioned media were obtained after a 16 h-incubation
of cells in serum-free medium containing 1 mg/ml BSA.
Proteins were precipitated in the presence of 80% ammo-
nium sulfate, solubilized and dialyzed against PBS. A
sandwich-type ELISA was developed for detection of hu-
man EREG using 3 μg/ml goat polyclonal antibodies for
coating on 96-well plates and a mouse monoclonal anti-
EREG (1 μg/ml) as the second antibody. Presence of
EREG was indirectly measured using goat anti-mouse
antibodies coupled to biotin and revelation was carried
out using streptavidin peroxidase and the TMB substrate.
Standard curves were obtained using recombinant hEREG
and assays were performed in duplicate or triplicate.
Measures were obtained with a SPECTRAmax spectro-
photometer and calculations were developed from lin-
ear curves (r > 0.98).
Gene expression analysis
Total RNAs extraction, real-time quantitative PCR (qPCR)
and PCR analyses were carried out as previously described
[22] using HPRT1, S16, α-tubulin and β-actin as reference
genes. Experiments were performed in triplicate or tetra-
plicate from two or three independent cell cultures or
from chicken and mouse tissues as indicated below. XBP1
splicing was monitored as reported before [22].
Small interfering RNA knockdown experiments
U87 cells were plated at a density of 105 cells per well in
six-well plates. Small interfering RNA (siRNA) against
human IRE1α (5′-GCGUCUUUUACUACGUAAUCU-3′)
was from Eurofins MWG Operon (Ebersberg, Germany).
ON-TARGETplus siRNA against XBP-1 (GCUCUUUCC-
CUCAUGUAUAC) and non-targeting siRNA (#D-001810-
01-20) were from Dharmacon (Lafayette, CO). Transfectionwas performed for 48 h using lipofectamine RNAiMAX
(Invitrogen) in accordance with the manufacturer’s proto-
col, with siRNA at a final concentration of 100 nM.Xenograft models
The Chorio-allantoic membrane (CAM) assay was devel-
oped as previously described [22]. At day 4 after im-
plantation, tumors were excised from the CAM and
pooled (n = 5 for each condition) before RNA extraction
using Trizol reagent. Intracranial implantation was
performed as follows: U87, SF126, SF188, NHA/TS
and NHATSR cells were orthotopically implanted in
8–9 weeks of age RAG2/γc immunodeficient mice [22].
Cells (2.5x105 cells, 3 μl) were implanted in the stri-
atum of the left cerebral hemisphere, 0.1 mm posterior
to bregma, 2.2 mm lateral and 3 mm in depth. For
Kaplan–Meier survival analyses, 18 mice were implanted
with U87Ctrl cells and half of them were treated by sub-
cutaneous injection of 400 μg Erbitux® three times a week
from day 4 to day 32 post-implantation. In vivo experi-
ments were performed at the animal facility Université
Bordeaux 1 (agreement n° B33-522-2) according to ethical
criteria approved by the Ministère de l′Enseignement
Supérieur et de la Recherche (MESR).Laser-capture microdissection
Tumors were xenografted in mice as described above. Brains
were recovered at different times and frozen at −80°C. Tissue
sections (30 μm) were obtained at −20°C using a CM3050 S
microtome (Leica) and were mounted on PEN-membrane
1 mm glass slides (P.A.L.M. Microlaser Technologies AG,
Bernried, Germany) that had been pretreated to inactivate
RNase. Frozen sections were fixed by incubation for 1 min
in pre-cooled (−20°C) 80% ethanol and stained with H&E
for 30 s. Sections were then rinsed with RNase-free water for
30 s, dehydrated in a series of pre-cooled ethanol baths (30 s
in 50%, 70% and 1 min in 100%) and air-dried. Immediately
after dehydratation, LCM was performed using a PALM Mi-
croBeam microdissection system version 4.0-1206 equipped
with a P.A.L.M. RoboSoftware (P.A.L.M. Microlaser Tech-
nologies AG, Bernried, Germany). Microdissection was per-
formed at 5X or 20X magnification. Total volumes of tumor
tissues captured on one single cap were in the 0.8- to 8.7 x
106 μm3 range and random areas were chosen within tu-
mors. RNA samples with a RNA-Integrity Number (RIN)
above 8 were kept for qPCR analyses after NanoDrop and
Agilent validation. Three tumors were analyzed for each
condition and qPCR were carried out in triplicates. Primers
specifically recognized cognate human sequences and did
not significantly cross-react with any mouse sequences as
determined both in total mouse brain tissues and mouse
brain sections obtained by LCM. Control qPCR were also
performed from tumor tissues after omitting the reverse
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complete run cycles.
Results
EREG expression in U87 glioma cells
Expression of EREG and HB-EGF, two members of the
EGF family, was analyzed in U87 cells in culture condi-
tions. Using transcriptome analysis, we observed that the
two transcripts were abundant both in wild type U87
(U87wt) cells and in cells transfected with the empty
vector (U87Ctrl cells), whereas ~100-fold (EREG) and
8-fold (HB-EGF) decreases were monitored in cells ex-
pressing an IRE1α dominant-negative protein (U87dn
cells) (Figure 1a). Similar results were obtained by
qPCR in independent cell cultures as well as in U87wtFigure 1 Expression analyses of EREG and HB-EGF in IRE1α-deficient c
strategy (U87dn vs. U87Ctrl cells) or the siRNA IRE1α knockdown methodolo
data (GEO, #GSE22385) and by qPCR. For knockdown analysis, IRE1α siRNA-tra
(si.Ctrl). SPARC and THBS1 mRNA levels were given for comparison. qPCR mea
determined by ELISA. Results are mean values ± SD. The dotted line represen
were deposited onto the chicken CAM and tumors were allowed to grow for
tumors at day 4. Bar = 2 mm. Lower panel: variation of EREG and HB-EGF tran
mean values of five pooled tumors ± SD. (d) Mouse model. Cells were intracr
d28 (U87Ctrl) and at d43 (U87dn) post-implantation. Brain sections were stain
(Bars = 300 μm). Tumor areas were dissected inside the tumor core in co
in infiltrative dn tumors (v, vi). Gene expression analyses (vii) were carried ou
of triplicates in three independent experiments (Exp. 1–3). NC, no change;→
value could not be determined. Visualization of amplicons after 40 cycles of qcells transfected with small interfering RNAs targeting
IRE1α (si.IRE1α) (Figure 1a). Thus, both dominant-
negative and siRNA knockdown approaches led to a
significant decrease in EREG mRNAs in cells under-
expressing IRE1α. As positive controls, SPARC and
THBS1 genes were upregulated to different extents.
Consistent values were obtained at the protein level by
using an ELISA against EREG (Figure 1b). U87Ctrl
cells released ~270 pg of diffusible EREG per million
cells daily, whereas EREG immunoreactivity was un-
detectable in U87dn cell-conditioned media (< 20 pg
per million cells per day).
Presence of EREG and HB-EGF mRNAs in U87 cells
was also monitored in human tumor xenografts using
the chicken chorio-allantoic membrane (CAM) and theells. Analyses were performed using either the dominant-negative
gy. (a) Fold-increase in gene expression was examined from microarray
nsfected U87wt cells were compared to nontargeting siRNA-treated cells
n values were ± SD. (b) EREG protein levels in cell-conditioned media as
ts the limit of detection of the measure. (c) The chicken egg model. Cells
4 days. Upper panel: microphotographs of U87Ctrl- and U87dn-derived
scripts levels in U87dn vs. U87Ctrl tumors as measured by qPCR. Data are
anially implanted into the left frontal lobe and tumors were collected at
ed with H&E (i, iv). Aspect of tumors before (ii, v) and after (iii, vi) LCM
ntrol animals (ii, iii) and multiple tumor cell bundles were collected
t by qPCR using HPRT1 as reference. Results are fold-increase ± SD
0, No Ct value obtained with U87dn tumors;→ ∞, value > 3 000; ND,
PCR (panel vii, right).
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planted onto the CAM and tumors were grown for
4 days. Under these conditions, U87dn-tumors were
small and merely avascular, compared to massive and
angiogenic U87Ctrl-tumors (Figure 1c, upper panel) [22].
Tumors were then excised and total mRNA was extracted
for qPCR analysis. EREG and HB-EGF mRNAs were
present in smaller amounts (~5- and ~2.5-fold decreases,
respectively) in U87dn-derived tumors as compared to
U87Ctrl tumors (Figure 1c, lower panel). These transcripts
were also quantified in the orthotopic glioma implantation
model in mice using LCM coupled to qPCR analysis
(Figure 1d). In these conditions, EREG and HB-EGF
mRNAs were readily detected in U87Ctrl-derived tumors
but not in U87dn-derived tumors (Figure 1d, panel vii).
Thus, mRNA production of these growth factors occurred
in an IRE1α-dependent manner in U87 glioma cells.
EREG induced glioma cell proliferation and migration
The effect of EREG on U87 cells was examined in cell cul-
tures at low serum concentration. U87dn cells incubatedFigure 2 Differential effects of EREG on morphology, growth and mig
selectively induced by EREG on U87dn cells. Cells were grown in the prese
U87Ctrl and U87dn cells are shown after 3 days in culture. Bar = 50 μm. (b
proliferation assay, cells were grown for four days. The total cell number w
U87Ctrl cells in the absence of EREG. Results are the mean of triplicates ± S
Transwell migration assay, cells were deposited in the migration chamber f
serum, with or without EREG. Results were expressed as fold increase ± SD
(*; p < 0.05). (c) EGF receptors are expressed in U87Ctrl and U87dn cells. D
depicted by transcriptomic (GEO, GSE22385; AffyID probe set numbers are
proteins in U87Ctrl and U87dn cells. For EGFR detection, cells were pre-inc
not with 30 ng/ml EREG for 20 min. Immunoblotting was performed using
actin. Signal intensities of p-EGFR bands were quantified and normalized (Nfor three days in the presence of EREG underwent notable
scattering, which was not observed with U87Ctrl cells
(Figure 2a). Such an effect has already been described
using HeLa epithelial cells [15]. In addition to its morpho-
logical effect, EREG induced proliferation and migration
of the two cell variants, these effects being more import-
ant in U87dn cells (Figure 2b). These results suggest the
presence of functional ErbB proteins on the membrane of
U87 cells.
Transcript and protein expression levels of ErbB1-4
were analyzed comparatively and quantitatively in the
two cell types. EREG was reported to bind preferentially
to ErbB1 and ErbB4, whereas ErbB2 does not bind any
known ligand but contributes as a co-receptor to signal
transduction [13,14]. Transcriptomic and qPCR analyses
indicated that the respective amounts of ErbB1, ErbB3
and ErbB4 mRNAs are similar in the two U87 cell vari-
ants (Figure 2c), the level of ErbB3 transcript being al-
most undetectable. Besides, the amount of ErbB2 mRNA
increased by ~1.5- to 4-fold in U87dn cells vs. U87Ctrl
cells. Only ErbB1 and ErbB2 proteins were detected byration of U87Ctrl and U87dn cells. (a) Morphological changes are
nce of 1% FCS with or without 30 ng/ml EREG. Photomicrographs of
) Effects of EREG on U87 cell proliferation and migration. In the
as reported as fold-increase of the standard value (1.00) obtained with
D. Mann–Whitney was performed for significance (*; p < 0.05). In the
or 15 h and were then allowed to migrate for 9 h in the absence of
of the number of migrating cells in the presence vs. absence of EREG
ifferential expression of ErbB1-4 mRNAs in U87dn versus U87Ctrl cells as
indicated) and qPCR analyses. (d) Presence of EGFR (ErbB1) and ErB2
ubated for 3 h in the absence of serum and were then stimulated or
antibodies against EGFR, phospho-Tyr1173-EGFR (p-EGFR), ErbB2 or β-
) to β-actin. The 1.0 value is used as the reference.
Table 1 Erbitux inhibits EREG-mediated proliferation of
U87 cells




U87Ctrl 130.1±4.4 98.3±8.6(*) 125.6±7.9 (ns)
U87dn 144.3±3.3 104.3±3.9(*) 131.6±8.8 (ns)
Cells were plated at 7,500 cells/cm2 in 96-well culture dishes and were grown
in the presence of 1% FCS in the presence or absence of EREG (30 ng/ml),
Erbitux® (200 μg/ml; cetuximab) and Herceptin® (830 μg/ml; trastuzumab).
Cells were counted in triplicate after four days of culture. EREG-induced cell
proliferation was presented as mean percentage ± SD of the total cell number
measured in the absence of EREG (100% reference value). Mann–Whitney was
performed for significance: Erbitux® vs. no antibody (*; p ≤ 0.05); Herceptin® vs.
no antibody (ns, not significant; p > 0.05).
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consistent with results reported by others in this cell
model [6,26]. Finally, treatment of U87Ctrl and U87dn
cells with EREG stimulated phosphorylation of the EGFR
(ErbB1) protein at Tyr-1173 residue (~10% and ~40% in-
creases in the two cell variants, respectively).
Next, we investigated the respective contribution of
ErbB1 and ErbB2 to cell proliferation promoted by
EREG. Cells were incubated in the presence of EREG
under low-serum conditions, with or without inhibitory
antibodies directed against either ErbB1 (Erbitux®) or
ErbB2 (Herceptin®). As shown in Table 1, Erbitux® al-
most completely abrogated EREG-induced cell prolifera-
tion of U87Ctrl and U87dn cells, whereas Herceptin®
had no significant effect. Thus, the effect of EREG on
U87 cell proliferation was mediated mainly through
ErbB1.
In order to validate the existence of an EREG autocrine
loop, a serial propagation of U87 cells was performed for
four passages in a serum-free medium in the absence of
growth factors. The culture medium was designed to
allow better detection of endogenous growth promoting
activities, including those of the EGF family [25]. Again,
stimulation with EREG in these conditions resulted in a
significantly higher growth rate of both U87Ctrl and
U87dn cells (Table 2). This effect was reverted by addingTable 2 Autocrine loop induced by EREG in U87 cells
Division time in days (R value)
U87Ctrl U87dn
no treatment 2.73 (0.99) 5.08 (1.00)
EREG 2.20 (1.00) 2.86 (0.99)
EREG/Erbitux® 3.08 (1.00) 4.50 (1.00)
anti-EREG 3.12 (1.00) 4.76 (0.99)
Cells were plated at 10 000 cells/cm2 in 24-well plates and grown for four
successive passages in serum-free condition in the presence or absence of
10 ng/ml EREG, with or without antibodies anti-ErbB1 (Erbitux®, 200 μg/ml)
or anti-EREG (5 μg/ml). Cells were counted at each passage and division
times were presented as best slopes obtained after four passages (29 days
of growth) and from a series of triplicate experiments. Regression lines include the
origin (R, correlation coefficient). Control mouse monoclonal antibody (isotype
IgG1) had no significant effect.either Erbitux® or anti-EREG antibodies. Interestingly,
EREG blocking antibodies also consistently increased
by 14% the U87Ctrl cell division time in the absence of
exogenous EREG and this effect was not observed in
U87dn cells under-expressing EREG. Thus, U87Ctrl
cells, but not U87dn cells, actively stimulated them-
selves by producing both EREG and ErbB1.Figure 3 Expression of EREG in human glioma cell lines. (a)
EREG immunoreactivity was measured by ELISA in culture media
conditioned by glioblastoma cell lines (U87, SF126, SF188),
immortalized/non-tumorigenic human astrocytes (NHA/TS) and the
NHA/TS tumor variant expressing the Hras oncogene (NHA/TSR). The
dotted line represents the limit of detection of the measure. The
tumorigenic potential of each cell type was evaluated by
immunohistochemistry after intracranial implantation of 250 000
cells and analysis of tumor progression at days 10, 20, 30 and 60
post-implantation. (+) tumorigenic, (−) not tumorigenic. (b) EREG
mRNA expression was represented as fold induction in glioma cells
vs. NHATS cells. qPCR was performed using HPRT1 as reference gene.
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xenograft tumor model. After implantation of U87wt
cells in mice brain, animals were treated for four weeks
with or without Erbitux® and tumor aggressiveness was
determined. As shown in Additional file 2, no significant
effect of Erbitux® was evidenced in this experimental set-
ting (see also ref. [27]), which may result of a limited
antibody delivery to tumor tissues. Besides, the autocrine
contribution of EREG is likely to be reduced in the
U87 glioma model, as these fast-growing tumors se-
crete other growth-promoting and angiogenic polypep-
tides and may exploit alternative signaling pathways
for expansion [22,28].
EREG expression and glioma malignancy
EREG mRNA and protein levels were monitored in sev-
eral human glioma cell lines. As shown in Figure 3a,
U87wt, SF126 and SF188 cells were highly tumorigenic
in the orthotopic implantation model in mice and re-
leased highly variable amounts of EREG protein (up toFigure 4 Characterization of U87Δ899 IRE1 RNase dominant-negative
IRE1α protein truncated at its cytoplasmic C-terminal end in the RNase dom
clones (R2, R3 and R7, upper panel) and in U87dn cells (lower panel). Cells
with DMSO only. Amplification of XBP1 transcripts was carried out after rev
PCR products were analyzed by electrophoresis on 2% agarose gels. XBP1s
(c) MIST transcripts were measured by qPCR in U87wt, U87Ctrl, U87dn a
The reference value (1.00) corresponds to the value obtained with U87wt cell
mRNA as standard. qPCR was performed in triplicate on three independent R
autophosphorylation in U87Δ899 cells. Immunoblotting analysis of total
2h-incubation with or without tunicamycin.200-fold differences). Moreover, non-tumorigenic NHA/
TS human astrocytes produced about five-times more
EREG than their highly oncogenic Hras-transformed
(NHA/TSR) counterparts. These results are consistent
with those obtained at the mRNA levels (Figure 3b) and
indicated that the release of EREG by these glioma cell
lines did not strictly correlate with tumor malignancy.
We then evaluated the clinical significance of EREG
expression in human gliomas, of which a significant per-
centage accumulates high levels of ErbB proteins. We
documented EREG mRNA production by transcriptome
mining using the Gene Expression Omnibus (GEO) and
Oncomine databases (Additional file 3). Microarray
analyses of gliomas at different grades of malignancy
indicated that EREG transcripts were detected in
highly variable amounts in tumor tissues, although no
clear relationship was established between EREG mRNA
levels and the glioma grade or brain tumor type. Individ-
ual cases presenting EREG upregulation were also ob-
served by using PCR approaches in both anaplasticcells. (a) The U87Δ899 RNase construct was designed to express an
ain. (b) Inhibition of XBP1 splicing in three different U87Δ899 RNase
were stimulated for 2 h with 10 μg/ml tunicamycin/DMSO (Tun) or
erse transcription using primers flanking the XBP1 mRNA splicing sites.
and XBP1u represent spliced and unspliced mRNA, respectively.
nd U87Δ899 cells subjected or not to tunicamycin treatment for 16 h.
s in the absence of tunicamycin. Results were normalized using HPRT1
NA preparations. Data are presented as mean ± SD. (d) IRE1 kinase
IRE1α (IRE1) and of phospho-Ser724-IRE1 (p-IRE1) proteins after a
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brain tissues [21].
EREG expression in relation to IRE1α
The relationship identified between IRE1α invalidation
and the decrease in EREG mRNA level was further mon-
itored in U87 glioma cells incubated with tunicamycin,
an antibiotic that inhibits N-linked protein glycosylation
and triggers ER-stress. In order to assess the respective
effects of the protein kinase and RNase cytoplasmic do-
mains of IRE1α on EREG expression, we designed an
IRE1α mutant (IRE1Δ899) truncated by 78 amino acids
at the C-terminal and invalidated for RNase activity
(Figure 4a). Three cell clones (R2, R3 and R7) were se-
lected for their expression of the artificial IRE1α iso-
form and inhibition of ≥ 90% of XBP1 pre-messenger
splicing under tunicamycin treatment (Figure 4b). Low
levels of MIST1 transcripts were consistently detected
in U87Δ899 cells (Figure 4c), in keeping with the fact
that MIST1 is a target gene of the mature XBP1 transcrip-
tion factor [29]. Conversely, IRE1α autophosphorylation
(phospho-Ser724-IRE1) was still effective in U87Δ899
clones and was upregulated with tunicamycin (Figure 4d).Figure 5 EREG mRNA expression in U87 cells is independent of IRE1 R
EREG transcripts by U87Ctrl, U87dn and U87Δ899 cells with or without tun
the reference value obtained in U87Ctrl cells at the beginning of the exper
represented as the mean of triplicate experiments ± SD. (b) siRNA knockdown ex
(si XBP1), nontarget siRNA-transfected cells (si Ctrl) or in untransfected U87wt cell
10 μg/ml tunicamycin. Presence of mRNA was monitored by qPCR. Resu
without tunicamycin and were normalized using HPRT1 mRNA detectionThus, the IRE1Δ899 construct acts as a selective
dominant-negative mutant of IRE1 RNase and does
not notably affect IRE1 kinase activity.
Kinetic expression of EREG was analyzed in U87 cell
mutants. EREG mRNA levels were similar in U87Ctrl
and in U87Δ899 cells in basal conditions and were tran-
siently and modestly (~2.5-fold) increased in the two cell
variants in response to either tunicamycin (Figure 5a) or
thapsigargin (not shown) treatments. Again, U87dn mu-
tant cells defective in both IRE1 kinase and IRE1 RNase
activities produced much lower amounts of EREG under
basal condition, a partial recovery of EREG transcript ac-
cumulation being observed after 4 to 8 h of incubation
with tunicamycin (Figure 5a). Thus, invalidation of IRE1
RNase activity did not compromise EREG expression
whereas the absence of both kinase and RNase functions
strongly affected its production. siXBP1 knockdown,
which achieved significant silencing of the XBP1 gene,
confirmed that EREG expression was independent of the
IRE1 RNase/XBP1 axis (Figure 5b).
Since JNK activation can be controlled by IRE1α kin-
ase activity [30], we further investigated EREG produc-
tion in the presence of the specific pan-JNK inhibitorNAse activity and of XBP1. (a) Kinetic analysis of the expression of
icamycin (Tun). qPCR values were presented as fold-increase relative to
iment (t = 0). HPRT1 was used as the internal standard and values are
periments. mRNA expression of XBP1 and EREG in XBP1 siRNA-transfected
s (− si). After transfection, U87wt cells were incubated for 6 h with or without
lts were expressed as fold-change relative to untransfected U87 cells
.
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tunicamycin-mediated induction of EREG in both U87Ctrl
and U87Δ899 cells after 6h of incubation (Figure 6a).
Thus, involvement of the JNK pathway for IRE1-
dependent regulation of EREG was irrespective of the
IRE1 RNase status. Moreover, tunicamycin partially
restored the ability of U87dn cells to accumulate
EREG transcripts and this inducible effect was also
strongly hindered by treatment with SP600125. Thus,
both IRE1-dependent and IRE1-independent path-
ways may converge in U87 cells toward JNK signaling
and EREG expression under tunicamycin treatment.
This is also consistent with the fact that JNK phos-
phorylation was increased by tunicamycin in all cell
variants, including U87dn cells (Figure 6b).
Discussion
EREG is a member of the EGF-like growth factor family
acting through ErbB tyrosine-kinase receptors andFigure 6 Effect of the pan-JNK inhibitor SP600125 on EREG
expression. (a) EREG transcript level was measured by qPCR in
U87 cells after a 6-h incubation with or without 10 μg/ml tunicamycin
and/or 25 μM SP600125. Results were expressed as fold-change relative
to U87Ctrl cells in the absence of Tun and SP600125 and were
normalized using the HPRT1 reference gene. Results are mean
values ± SD. (b) Kinetics of JNK phosphorylation in the presence
of 10 μg/ml tunicamycin. U87 cells were treated with or without
Tun as above. Cell extracts were used for immunoblotting to
measure activation of JNK using an anti-phospho-JNK (p-JNK) antibody
and antibodies directed against the total (JNK) protein. α-tubulin was
used as the reference.functionnally associated to cell proliferation, survival
and migration of a wide range of cell types [2,12,31,32].
Its reported functions in mammals include tissue protec-
tion, role in development, reproduction, tissue repair
and immune-related responses [33-36]. EREG protein is
synthesized as a 163 amino-acid transmembrane precur-
sor and is converted to a diffusible peptide by proteolytic
cleavage [12]. Its activities require binding to ErbB1 or
ErbB4 transmembrane receptors and transduction sig-
naling through their dimeric combinations with any
members of the ErbB family [2,13].
Increased expression of EREG was associated to carcin-
oma growth, invasion and angiogenesis [16,19,20,23,37]
and correlated with poor prognosis [18]. However, the
possible implication of EREG in glioma development has
not yet been addressed, even though the pathological sig-
nificance of EGFR has been well established in this
pathology. High numbers of wild type or mutated ErbB1
receptors were often detected in primary glioblastomas
and in WHO grade II and III oligodendrogliomas [3,4].
The upregulation of the three other ErbB family members
in malignant glioma has also been documented [4,5,7].
In this work, EREG expression analyses were per-
formed in several glioma cell lines and were also inven-
toried in high-grade gliomas from the GEO and Oncomine
databases. Both practical and database approaches led to
convergent results and indicated that gliomas, as reported
for breast cancers [16], produced EREG in highly variable
amounts. Same disparities were also observed in gliomas
when considering other EGF-like peptides [9,10]. The rea-
sons underlying these modulations likely reflect the wide
heterogeneity of gliomas and the possible intervention of a
set of transcription factors involved in EREG expression
and tumor progression [38-44].
We also showed that the U87 glioma cell line expressed
EREG under the dependence of the UPR sensor IRE1α. In-
hibition of IRE1α activity, either conducted at the mRNA
(siRNA knockdown) or protein (dominant-negative strat-
egy) levels, down-regulated EREG transcript accumulation.
In addition, chemical inducers of the UPR such as
thapsigargin [45], tunicamycin (this work) or Npi-0052
[46], promote EREG mRNA accumulation in cells,
which again suggest a functional link between ER-
dependent signaling and EREG expression (see Figure 7,
summary illustration).
IRE1α is a bifunctional kinase/RNase enzyme. We eval-
uated the possible contribution of IRE1 RNase to EREG
expression by using a C-terminal truncated IRE1α mu-
tant whose production in cells led to RNase inhibition
while maintaining IRE1α autophosphorylation capabil-
ities. Using this mutant, we observed that EREG was
expressed at similar rate in RNase-deficient cells as in
control cells. In addition, siRNA-mediated knockdown
of XBP1 had no significant impact on EREG transcript
Figure 7 Proposed scheme depicting the relationship between IRE1α and the autocrine loop mediated by EREG through ErbB1. IRE1α
is a transmembrane protein of the endoplasmic reticulum (ER) and an upstream activator of the JNK to EGFR signaling ①. IRE1 kinase, but not
the IRE1 RNase domain, contributes to the high level of EREG production in these cells. Treatment of the cells with the UPR inducers tunicamycin
and thapsigargin increases EREG expression using both IRE1α-dependent① and IRE1α-independent② pathways. EREG secretion leads to the activation
(③ and④) of EGFR, a protein constitutively expressed by U87 cells. The resulting effect is the autocrine activation of cell proliferation and migration.
HB-EGF is another ligand of EGFR and is also expressed by U87 cells. Endogenous expression of EREG and HB-EGF provides a rationale for
the consistent level of EGFR autophosphorylation observed under basal conditions. EREG-mediated autocrine loop and sustained activation
of EGFR potentially contribute in glioma initiation and progression.
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is subordinated to the presence of IRE1α but is not sig-
nificantly affected after blockade of either IRE1 RNase
or XBP1 functions.
Since IRE1 kinase activity is an upstream mediator of
JNK signaling [30], we used the pan-JNK inhibitor
SP600125 in order to examine the possible involvement
of the IRE1/JNK transduction pathway as an alternative
to the IRE1 RNase-dependent axis for production of
EREG. The two pathways can be functionally dissociated
[47,48], which is consistent with the fact that IRE1α au-
tophosphorylation status in U87 cells does not strictly
correlated with the IRE1 RNase-mediated splicing of
pre-XBP1 mRNA [22]. As reported here, SP600125 de-
creased EREG mRNA expression in wild type cells and
in cells selectively blocked for IRE1 RNase activity, sug-
gesting that both the IRE1 kinase domain and JNK con-
tributed to EREG expression. Two transcription factors
activated downstream of JNK signaling (egr-1 and c-jun[38,44,49]) were found to modulate EREG expression
thus providing a possible molecular link between activa-
tion of IRE1α and EREG expression. Interestingly, we
showed that U87dn cells expressing low to undectable
amounts of IRE1α also responded to tunicamycin treat-
ment by increasing JNK phosphorylation and EREG mRNA
accumulation. Therefore, IRE1-independent pathways may
also converge on EREG expression through JNK signaling.
Several possible explanations may support this result, in-
cluding the existence of secondary stimulatory loops
mediated by cytokines production independently of the
UPR [49,50].
U87 cells release EREG in high amounts and select-
ively co-express ErbB1 and ErbB2 proteins, but not
ErbB3 and ErbB4 proteins. The presence of an autocrine
loop mediated by EREG through ErbB1 was demon-
strated by the fact that anti-ErbB1 and anti-EREG anti-
bodies (but not anti-ErbB2 antibodies) reduced the basal
cell proliferation rate in culture, which was not observed
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autocrine effect mediated by EREG has also been reported
in normal cells [31,32]. In addition, other EGF-like ligands
such as TGFα and HB-EGF are involved in self-activation
loops in gliomas producing ErbB1 [2,9-11].
Conclusion
Our data strongly support the view that autostimulatory
effects involving EREG expression under the control of
IRE1α may be expected in different subtypes of gliomas.
Over-production of EREG may occasionally contribute
to glioma cell growth and migration as well as to sec-
ondary effects in brain cancer pathology, including vas-
cular remodeling and reactive gliosis [23,51].
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